Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
MOTS-c is a 16-amino-acid peptide that the human body makes from its mitochondrial DNA; a synthetic version is promoted online for blood sugar, weight loss, endurance and ageing. The strongest evidence for it comes from animal studies: in mice, injections improved the handling of glucose, limited weight gain on a high-fat diet and let old mice run farther. No published or posted study has given MOTS-c to a person, so there is no evidence in people that it helps, no human safety data and no tested dose; the one trial we found registered, planned for 120 adults, is recruiting.
This review keeps three kinds of study apart: those that gave MOTS-c to people (none has reported), one company trial of an analogue, which is a different molecule, and those that only measured the body’s own MOTS-c. Measuring someone’s own level of a peptide is not a test of giving it. The review is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. A draft HHS policy says it doesn’t intend to act against some compounding; that isn’t approval.
- Evidence in people
- None for MOTS-c itself. No published or posted study has given it to a person.
- The claim you’ve heard
- Improves blood sugar, weight and endurance: animal studies only, not tested in people.
- Doses tested in people
- None. The doses quoted online come from no study in people.
- Sport
- Prohibited at all times. WADA names it in class S4.4.1 on its 2026 and 2027 Lists.
What MOTS-c is
MOTS-c stands for “Mitochondrial Open Reading Frame of the 12S rRNA-c”. It is a chain of 16 amino acids encoded in mitochondrial DNA (the DNA carried by mitochondria, the structures in a cell that produce its energy), first described in 2015, and it has been detected in human blood and muscle. What is sold under the name is, in the FDA’s words, “reported to be a synthetic version”.
The name can cover more than one substance. MOTS-c exists as a free base and as an acetate salt, which the FDA treats as “different pharmaceutical ingredients”; HHS’s draft policy, described below, names only the acetate. Analogues, altered versions such as CB4211, are different molecules again, and the FDA’s review says that such substances “are not interchangeable because they can have different safety and efficacy profiles.”
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: MOTS-c is not FDA-approved, and the FDA’s staff proposed keeping it off the list of ingredients that pharmacies can compound from (make into a medicine for one patient), while its advisory committee, HHS says, voted in favor. HHS, the federal department the FDA belongs to, says in a draft policy that it does not intend to act against compounding of single-ingredient MOTS-c acetate injections on a patient’s prescription under set conditions; that is not FDA approval.
As of November 19, 2026, MOTS-c is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient MOTS-c acetate as a subcutaneous or intramuscular injection for a patient-specific prescription when the policy’s conditions are met; HHS’s notice says the policy “is not binding on HHS or the public”, and it is not FDA approval.
The FDA’s own review
Before an advisory committee meeting in July 2026, the FDA’s staff wrote: “we propose not adding MOTS-c (free base) or MOTS-c acetate to the 503A Bulks List.” Their reasons: the substances are “not well-characterized”, their use in compounding is unknown, and there are no animal or laboratory data “to inform safety considerations” and “no clinical studies to assess the safety and effectiveness” in people.
The advisory committee
HHS’s policy document says the committee “voted in favor of both forms”. The FDA has posted no minutes or vote count; a news report and a law firm’s summary both give 7 in favor, 5 opposed and 2 abstentions. An advisory vote does not bind the FDA.
The FDA’s safety-risks page
By HHS’s dates, MOTS-c was in the FDA’s Category 2, for nominated substances with “significant safety risks”, “from September 29, 2023, until April 22, 2026”. It left because the nomination was withdrawn, not because the FDA found it safe. The FDA’s page still lists it, as “MOTs-C”, and says: “FDA lacks important information regarding any safety issues raised by MOTs-C, including whether it would cause harm if administered to humans.”
HHS’s draft policy and its conditions
For MOTS-c the policy names the acetate only, in “subcutaneous or intramuscular injectable dosage forms” (under the skin or into a muscle). Among its ten conditions:
- the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”;
- it is compounded on a patient-specific prescription;
- the raw ingredient has a certificate of analysis for identity, purity, potency and contaminants;
- compounders report serious adverse events.
On safety, HHS writes that “a randomized placebo-controlled trial of a MOTS-c analogue reported no serious adverse events at an exposure well above the compounded regimen and the rodent studies reported metabolic benefit without systemic toxicity.” It names neither the trial nor the studies, and does not say what “the compounded regimen” is. The FDA and HHS weigh the same record differently, and neither cites a study that gave MOTS-c to a person.
The policy is interim: HHS “may revisit” it “if, among other things, a safety signal or product quality issue arises”. It states: “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.” Comments on the draft closed on November 13, 2026, and the Federal Register held no final version and no rule when we checked.
Sport
WADA names MOTS-c in class S4.4.1 of its Prohibited List, among “Activators of the AMP-activated protein kinase (AMPK)” (an enzyme involved in how cells use energy), prohibited at all times on the 2026 and 2027 Lists.
Claims you’ll see, and why sources disagree
Pages about MOTS-c disagree for three reasons:
- Mouse results are written as human results, and overstated. Pages say what “patients” notice within weeks, though no study has measured energy or fatigue after MOTS-c in people. A mouse lifespan result that was not statistically significant overall becomes “extended lifespan”.
- A measured level is read as a tested treatment. “Levels fall with age” rests mainly on one study of 78 men, and measuring a level doesn’t test what happens when MOTS-c is given.
- A different molecule stands in for MOTS-c. The only trial results in people are for the analogue CB4211, and HHS’s safety reasoning cites a trial of “a MOTS-c analogue”.
“Not tested in people” does not mean “doesn’t work”. It cuts both ways: MOTS-c has not been shown to help people, and it has not been shown to be safe for them.
| Claim | Level of evidence | Verdict |
|---|---|---|
| Improves insulin sensitivity, reverses diabetes | Animal studies | Mice handled glucose better over days to weeks. Not tested in people. |
| Causes weight loss | Animal studies | Over 8 weeks, mice on a high-fat diet gained less weight; mice on a normal diet did not change. |
| Mimics exercise, improves endurance | Animal studies | Treated mice ran longer. In people, only the body’s own level has been measured around exercise. |
| Extends lifespan; its genes are tied to long life | Animal studies (one experiment); a gene study in people | Overstated: the mouse result was not statistically significant overall, and the gene variant was about as common in 736 Japanese centenarians as in others. |
| Reduces inflammation; protects memory | Animal and lab studies, with contrary findings | Lower inflammatory markers in treated mice; the opposite in one lab study of human repair cells. In mice it did not reach the brain or change memory tests. |
| Preserves muscle and bone | Animal studies | Less muscle loss and less bone loss in two mouse models. A 2019 paper on fracture healing was retracted in 2021. |
| Safe, and well studied in people | Not tested in people | Not established: no human safety data have been reported. The FDA identified no “human exposure data for MOTS-c via any route of administration”. |
| A “standard” dose, 5 to 10 mg two or three times a week | Not tested in people | Practice that no trial set, printed on telehealth and protocol pages. No published or posted study has tested any dose in people. |
What the evidence consists of
The evidence is set out by level, the strongest first.
Given to people: MOTS-c itself
No such study has reported, and the FDA’s review of May 2026 found none. Nothing has been reported in people outside trials either: our searches of PubMed and ClinicalTrials.gov on November 19, 2026 found no case series or case report, and one trial, which has no results. Other trial registries, China’s among them, were not searched.
MOTS-MET (NCT07505745) is a phase 2a, randomized, double-blind, placebo-controlled trial in China, planned for 120 adults with prediabetes and a body mass index of 27 to 40. They receive MOTS-c or placebo by injection under the skin once a day for 12 weeks. The main outcomes are insulin sensitivity and adverse events. The trial began in February 2026 and was registered in March, after it had started. The record discloses neither the dose nor the form of MOTS-c, and we found nothing else about its industry sponsor, Hudson Biotech.
Given to people: the analogue CB4211
CB4211 is an analogue developed by CohBar, Inc., whose founder, Pinchas Cohen, co-discovered MOTS-c and is a listed inventor on its patent rights. In the last part of a randomized, placebo-controlled phase 1 trial (NCT03998514), completed in 2021, 20 adults with obesity and fatty liver disease had a daily injection under the skin for four weeks: 11 received CB4211 and 9 placebo. The results exist only as a company press release.
| Change over four weeks | CB4211 (11 people) | Placebo (9 people) |
|---|---|---|
| ALT, a liver enzyme | -21% | 4% |
| AST, a liver enzyme | -28% | -11% |
| Glucose | -6% | 0% |
| Liver fat on MRI (absolute change) | -5.03% | -4.88% |
The company reported the first three differences as statistically significant, by several unadjusted t tests on exploratory outcomes. Liver fat fell in both groups, which differed at the start, and participants lived in the study unit throughout. It reported “no serious adverse events”. Injection-site reactions were the common event, and had earlier led the company to suspend the trial and change the formulation. No pharmacokinetic, antibody or per-dose results were ever released. CohBar later wrote that it did not believe this formulation “is suitable for further development”. A different molecule, tested in 11 people for four weeks, cannot stand in for MOTS-c.
Measured, not given: the body’s own MOTS-c
Many studies have measured MOTS-c in blood or muscle, or studied a gene variant, without giving the peptide to anyone.
The blood tests disagree. In the one check against mass spectrometry, in 20 healthy people, readings of 45.9 to 218.5 ng/mL from a commercial antibody kit “could not be confirmed”, although the method could detect 100 pg/mL (0.1 ng/mL). Average values in adult comparison groups run from 13.67 pg/mL in one study to 408.67 ng/mL in another, with the same kit named in both; the lower figure is below that kit’s stated minimum, so a unit error cannot be ruled out.
The results point in different directions.
- Age. In one study of 78 healthy men, from the discoverers’ group, blood levels were 11% and 21% lower in the middle-aged and older men than in the young, while muscle levels were about 1.5-fold higher.
- Exercise. In ten young men, cycling raised MOTS-c 11.9-fold in muscle and about 1.5-fold in blood. Three other studies found little or no change.
- A gene variant, K14Q. A 2015 commentary proposed that it might help explain Japanese longevity; a 2021 study found it in 7.7% of 736 Japanese centenarians and 7.5% of controls.
None of these studies tested whether taking MOTS-c helps.
Animal studies
| Study | Animals | What was given | What happened | Funding or limits |
|---|---|---|---|---|
| Lee and colleagues, 2015 | Male mice, 6 to 10 per group | Daily injections into the abdomen, 4 days to 8 weeks | Faster glucose clearance. Over 8 weeks on a high-fat diet, less weight gain with the same food intake; no weight change on a normal diet. In a 4-day test on a normal diet, modest falls in weight, food intake and glucose. | Discoverers’ group; ties to CohBar declared |
| Reynolds and colleagues, 2021 | Male mice, 5 to 12 per group | Injections for 2 weeks, or through late life | Old mice ran about twice as long and as far. Memory tests did not change. Lifespan: “a trend”, not significant overall (P = 0.23). | Discoverers’ group; ties to CohBar declared |
Given by mouth, MOTS-c “did not result in any significant improvements” in a mouse model in which the injected peptide worked, and in mice it did not cross from the bloodstream into the brain (both from papers testing the authors’ own analogue of MOTS-c). Other studies reported less muscle loss in mice with both hind legs in a cast for 8 days; in a 2016 study read as an abstract only, less bone loss in mice after removal of the ovaries; and slower tumour growth in mice carrying human ovarian-cancer cells.
Almost every study injected MOTS-c into the abdomen, which is not a route used in people. Groups were often 3 to 10 animals, mostly treated for 3 days to 4 weeks; the longest daily dosing found is about 23 weeks, in six mice. The FDA found no dose-finding study and no toxicology study of any kind. In the FDA’s words, “the clinical relevance of the findings of these nonclinical studies is currently unknown”.
Lab studies and how it is thought to work
The FDA’s review says: “the molecular target(s) through which MOTS-c acts remains unknown. As such, it is difficult to predict which organs might be targeted and affected by MOTS-c.” In lab studies of cultured cells:
- In cells engineered to overproduce MOTS-c, the active form of folate fell (less so when the peptide was added from outside), and MOTS-c switched on AMPK. Its discoverers wrote that “MOTS-c shares many effects with the antifolate drug methotrexate”.
- These experiments typically used 10 micromolar peptide. Whether blood or tissue reaches that level after an injection is unknown.
- One finding runs the other way. In fat-derived repair cells from people with obesity, added MOTS-c “reduced proliferation, increased expression of senescence-associated genes (p16, p21), and upregulated TNF-α” (the cells divided less and showed more markers of ageing and inflammation).
Who produced the research. The founding papers come from the groups of Pinchas Cohen and Changhan Lee at the University of Southern California, funded mainly by public and charitable grants. Their 2021 paper declares: “P.C. and C.L. are consultants and shareholders of CohBar, Inc.” Most of the headline findings on metabolism, exercise and ageing are theirs, and much of the bone, fat-tissue and liver work shares authors from one group in China. A record that rests mostly on a peptide’s discoverers, with no dose-response work and little independent replication, is itself a reason for caution.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. No published or posted study has compared one dose of MOTS-c with another in people, so no amount can be called optimal.
Doses tested in people
None. No published or posted study has given MOTS-c to a person by any route. The one trial we found registered gives an undisclosed “Fixed dose” once a day for 12 weeks and has no results. The analogue CB4211 is a different molecule of undisclosed structure, so the dose in its trial is not a MOTS-c dose.
Doses in common use
These are amounts in circulation: practice that no trial set. The reference sources state no amount: a research foundation’s report (“Dose: Not established”), an anti-doping agency’s page and two published reviews.
- The recurring figure: 5 to 10 mg per injection under the skin, two or three times a week, often in cycles of 4 to 12 weeks with a break. Five publishers print the amount, four at that frequency and one at “2 to 5 times per week”: three telehealth publishers, a protocol site and a protocol aggregator.
- Its stated origins. Where the pages name one, it is mouse doses scaled by body weight, “peptide synthesis convention”, clinic experience or another web page. The figures also match the vial strengths in a withdrawn pharmacy nomination to the FDA, which no page we read names as its source.
- The same range on other schedules. Sellers’ articles and a clinic’s summary of online guides give about 5 to 10 mg as a weekly total. A clinic page and a telehealth article give about 5 mg per injection three to five times a week, timed to exercise, though the human exercise studies gave no MOTS-c.
- The spread is wide. A “research use only” seller’s page starts at 200 micrograms a day and a compounding pharmacy’s gives 0.5 to 1 mg, daily or up to five times a week, naming no source; a seller’s article reaches “10-15mg per injection” and a telehealth chart 10 mg a day, 70 mg a week. Schedules run from daily to a clinic’s once every five days, its own “clinical judgment about pulsed signaling, not a finding lifted from a trial”, and one seller’s pages carry at least five schedules.
What the pharmacology supports, and what it doesn’t
- Amount: not measured. The animal studies “have not evaluated the dose-response relationships for the effects of MOTS-c in vivo”, in the FDA’s words. We convert none of their doses; every amount above is convention.
- Breakdown in blood: measured, in a test tube. Human blood broke MOTS-c down quickly, which the FDA wrote “raises the question as to whether exogenous administration of MOTS-c to humans can generate pharmacologically active concentrations of the peptide over time.”
- Route: measured in animals only, almost always by injection into the abdomen (above); none of the studies we read gave it into a vein.
- How often, and how long: cannot be inferred. Frequency follows from half-life, and none has been measured in people or animals. The MOTS-c trial and the analogue’s trial each chose once a day, a design choice, not a finding; the longest daily dosing found in animals is about 23 weeks.
- Monitoring: inferred from mouse studies, the analogue’s trial and the FDA’s concern about injected peptides: blood sugar, injection sites and signs of an immune reaction.
What nobody knows. Whether an injection produces an active level in a person, and what it does there over weeks or years.
What common protocols get wrong
- Human trials that could not be found. A seller’s articles describe trials “involving 180 participants” and “340 participants in published trials” and name none; the two trial-like titles in one source list were not found in PubMed, and the identifiers beside them belong to papers on other subjects. A telehealth chart describes “A phase I safety study in healthy adults”; the DOI of the reference it marks resolves to a 2020 paper on liver cancer.
- Mouse doses scaled to people, and misreported. Of the four publishers who call their figures scaled animal doses, two pages of one start from different mouse doses and reach different ranges, and the other pages name no starting dose. One of the two gives the dose of a paper’s short insulin-sensitivity experiments as that of its 8-week weight experiment, which used a lower one.
- A half-life, absorption figure or peak time, none of them measured. Five pages print one, none with a source. Another describes “A small human pharmacokinetic study” that neither we nor the FDA found.
- A vial strength captioned as a dose. One page, in one caption, calls the nomination’s strengths doses, though the caption adds “not a recommendation” and the rest of the page says there is no approved dose. The nomination, as the FDA reproduces it, gives no dose, frequency or duration.
- Cycles, breaks and combinations that no study tested. Four pages say a break prevents “receptor desensitization” or “tachyphylaxis”, though no receptor for MOTS-c has been identified and no study in any species compared continuous with interrupted dosing, or one cycle length with another. One aggregator marks MOTS-c combined with each of four other substances “Safe”, and the FDA records a clinic promoting a “Cocktail IV Therapy” containing MOTS-c; no combination has been studied.
The dose of any prescribed medicine is the prescriber’s decision for one patient.
Safety, and who should be most cautious
No adverse event from MOTS-c has been reported in people, because no study has reported giving it to people. That is an absence of data, not evidence of safety. In the FDA’s words, “potential safety risks associated with the use of MOTS-c in humans are unknown.”
- Outside studies. The FDA’s adverse-event database held no MOTS-c reports through March 9, 2025: weak reassurance, since compounders “generally do not report adverse events to FDA”.
- Immune reactions, the FDA’s main concern. Its safety-risks page says compounded MOTS-c “may pose significant risk for immunogenicity for certain routes of administration” (an immune reaction against the peptide). Its review adds that the consequences “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions”, and that antibodies could neutralize “the endogenous peptide counterpart”, the body’s own MOTS-c. There are no MOTS-c data either way.
- Animal safety studies. The FDA found none: no acute, repeat-dose, genetic, reproductive or cancer toxicity study. The nearest things are side-checks inside two cancer experiments in mice (one of five mice per group for 30 days), which reported little or no effect on the organs they checked.
- Theory: who should be most cautious. People on glucose-lowering medicines; people for whom folate matters, as in pregnancy or on methotrexate; and people with cancer or with tissue under repair. The reasons come from mice and cells: MOTS-c lowered blood sugar in mice, in cells it acted on folate in a way its discoverers compared with methotrexate, and its lab effects on cell growth run both ways. None of this has been observed in a person.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy, breastfeeding | No data in people or animals. The one trial excludes both. | The FDA’s review; the trial record |
| Under 18 | No data on giving MOTS-c. | The trial enrols adults only |
| Cancer, now or in the past | The FDA identified no carcinogenicity study. The trial excludes “Active malignancy requiring treatment”. | The FDA’s review; the trial record |
| Diabetes, or glucose-lowering medicines | Not studied; the trial excludes both. Added lowering of blood sugar is possible. | The trial record; animal studies; theory |
| Other medicines | No interaction of any kind has been studied. | No studies |
| Tested athletes | Prohibited at all times. A doping-control test method was published in 2019. | WADA’s 2026 and 2027 Lists |
Product quality
Two things are sold as MOTS-c: a medicine compounded by a pharmacy on a prescription, and vials sold online labelled “research use only”.
Compounded. In May 2026 the FDA’s staff found that the certificate of analysis submitted for MOTS-c acetate, the form HHS’s policy names, showed a purity of “99.2%” but no results for impurities, aggregates, microbial contamination, endotoxin or residual solvents. HHS says that has changed: “lot-specific certificates from FDA-registered manufacturers report the impurity, residual solvent, endotoxin, and microbial results” that the FDA found missing. Those certificates are unpublished, and we could not examine them.
“Research use only”. HHS’s policy speaks of “research-use-only peptides supplied by foreign manufacturers that pose a safety risk to US patients”. We found no published laboratory analysis of MOTS-c products. A commercial testing company (not peer-reviewed; samples sent in by customers and vendors) lists 95 tests of MOTS-c from 23 research-peptide vendors in 2026: 30 passed its standard, 59 failed and 6 were incomplete. Most failures were on purity against a strict bar, but in 10 tests the vial did not test as MOTS-c. A 2026 preprint, not peer-reviewed, on 6,441 samples of fourteen other online peptides reported that “41.6% to 71.1% of samples failed to meet basic quality criteria” and that “measurable endotoxin contamination was present in 15% of samples”. None of these figures concerns pharmacy-compounded medicines.
What we make of it
This section is our judgment, not a finding.
On the evidence, MOTS-c is unproven and experimental: no study has reported giving it to a person. A benefit is plausible, but the case is indirect: the body makes it; mice given it handled glucose better, gained less weight on a high-fat diet and performed better in old age; and cell studies give a partial account of how. That justifies the trial now under way. It is not evidence that MOTS-c helps a person.
The hype outruns the evidence wherever a page talks about people: what “patients” notice, how soon, a “standard” dose, a safety “profile”. None of it comes from a study in people.
With no trial in people, prescribing MOTS-c is prescribing on animal evidence and theory: there is no dose tested in people, there are no human safety data, and nobody can yet tell a patient how likely a benefit is. A patient should hear that before anything else, and may reasonably decide to wait for the first trial.
For MOTS-c to help a person, each of these would have to be true, and none is established:
- an injected dose reaches tissues at a level that does something, which the FDA itself questions;
- what happens in mice given MOTS-c into the abdomen also happens in people given it under the skin;
- the effect is large enough to matter beside diet, exercise and, for weight and bone, the drugs the FDA has approved;
- repeated injections do not provoke immune reactions or other harms that no study has yet looked for.
Until the first trial reports, we regard any use of MOTS-c in people as use ahead of the evidence. For whom it might be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- The first trial in people. MOTS-MET estimates its primary completion for February 2027 and its study completion for May 2028.
- A pharmacokinetic study in people. A measured half-life would turn “cannot be inferred”, above, into evidence.
- A final policy or rule. HHS’s notice says “FDA’s future rulemakings may propose adding some or all of these peptides to the 503A bulks list”.
Common questions
Has MOTS-c been tested in people?
No. No published or posted study has given MOTS-c to a person. One placebo-controlled trial, planned for 120 adults with prediabetes, is recruiting and has no results. A trial of an analogue, a different molecule, and studies that measured the body’s own MOTS-c are not tests of giving it.
Does MOTS-c help with weight loss?
It has not been tested for weight loss in people. In animal studies, mice on a high-fat diet gained less weight over 8 weeks when given MOTS-c, and mice on a normal diet did not change.
Can a doctor prescribe MOTS-c?
A compounded MOTS-c medicine is dispensed only on a prescription written for one patient, and because MOTS-c is not FDA-approved, any such prescription is for a compounded medicine. In announcing a draft interim policy, HHS said it “does not intend to take enforcement action” over single-ingredient MOTS-c acetate injections compounded for such a prescription when its conditions are met. That is not FDA approval.
What dose of MOTS-c is used, and how often?
No dose and no schedule have been tested in people: the one trial we found registered gives an undisclosed dose once a day and has no results. The amount that recurs online is 5 to 10 mg under the skin two or three times a week, on telehealth and protocol pages: practice that no trial set. How often MOTS-c would need to be given cannot be worked out, because its half-life has never been measured. The dose of any prescribed medicine is the prescriber’s decision for one patient.
What are the side effects of MOTS-c?
Nobody knows, because no study has reported giving MOTS-c to people. That is an absence of data, not evidence of safety. The FDA’s stated concerns are immune reactions to an injected peptide and impurities in the product.
Sources
Show all 36 sourcesHide sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: MOTS-c-Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate). U.S. Food and Drug Administration, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document with Appendices A and B). U.S. Department of Health and Human Services, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, document 2026-22192). Federal Register, 2026.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, 2026.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. U.S. Food and Drug Administration, 2026.
- 2026 Prohibited List. World Anti-Doping Agency, 2025.
- 2027 Prohibited List. World Anti-Doping Agency, 2026.
- MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (MOTS-MET), NCT07505745. ClinicalTrials.gov, 2026.
- A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease, NCT03998514. ClinicalTrials.gov, 2021.
- CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity. CohBar, Inc. (GlobeNewswire release reproduced by BioSpace), 2021.
- CohBar, Inc. Annual Report on Form 10-K for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission, 2023.
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
- Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Communications in Mass Spectrometry, 2019.
- MOTS-c modulates skeletal muscle function by directly binding and activating CK2. iScience, 2024.
- A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY), 2021.
- Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates Aβ1-42- or LPS-Induced Memory Impairment through Inhibiting Neuroinflammation. ACS Chemical Neuroscience, 2021.
- Orally administered MOTS-c analogue ameliorates dextran sulfate sodium-induced colitis by inhibiting inflammation and apoptosis. European Journal of Pharmacology, 2023.
- Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY), 2020.
- MOTS-C levels in individuals with and without obesity and its association with inflammation, insulin resistance and endothelial dysfunction. Archives of Endocrinology and Metabolism, 2025.
- Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. Journal of Applied Physiology, 2021.
- Circulating mitochondrial-derived microproteins at rest and in response to an acute bout of endurance exercise in individuals with cerebral palsy. Experimental Physiology, 2026.
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radical Biology and Medicine, 2026.
- Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study. Journal of the American Heart Association, 2025.
- The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?. Aging Cell, 2015.
- Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. American Journal of Physiology Endocrinology and Metabolism, 2024.
- Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochemical and Biophysical Research Communications, 2016.
- Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes. Cell Reports, 2021.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Advanced Science, 2024.
- MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. Acta Biochimica et Biophysica Sinica, 2024.
- Mitochondrial-derived peptide MOTS-c activates metabolic signaling but blunts reparative function in human mesenchymal stromal cells. Inflammation and Regeneration, 2026.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org, 2026.
- MOTS-c (Cognitive Vitality Report). Alzheimer’s Drug Discovery Foundation, 2025.
- What is the MOTS-c peptide?. U.S. Anti-Doping Agency, 2024.
- Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International Journal of Molecular Sciences, 2026.
- Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks. Cureus, 2026.
